Probiotics to Influence Fat Metabolism and Obesity

• US 20080267933A1
• Filed: 10/02/2006
• Published: 10/30/2008
• Est. Priority Date: 10/07/2005
• Status: Abandoned Application

• Current Assignee: CHR Hansen Holding A/S
• Original Assignee: Arla Foods Amba
• Inventors: Ohlson, Kajsa, Mahlapuu, Margit, Svensson, Ulla
• Application Number:
  US12/089,433
• Publication Number:
  US 20080267933A1
• Time in Patent Office: Days
• US Class Current: 424/93.45
• CPC Class Codes: A23L 33/135 Bacteria or derivatives thereof, e.g. probiotics
• CPC Class Codes: A61K 35/745 Bifidobacteria
• CPC Class Codes: A61K 35/747 Lactobacilli, e.g. L. acidophilus or L. brevis
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C12N 1/205 Bacterial isolates
• CPC Class Codes: C12R 2001/01 Bacteria or Actinomycetales ; using bacteria or Actinomycetales
• CPC Class Codes: C12R 2001/23 Lactobacillus acidophilus
• CPC Class Codes: C12R 2001/245 Lactobacillus casei
• CPC Class Codes: Y02P 60/87 Re-use of by-products of food processing for fodder production

Abstract

Use of probiotic bacteria for the manufacture of a food product, feed product, dietary supplement, nutritional product, natural remedy, pharmaceutical active formulation and medicinal product to be used for controlling weight gain, preventing obesity, increasing satiety, prolonging satiation, reducing food intake, reducing fat deposition, improving energy metabolism, enhancing insulin sensitivity, treating obesity and treating insulin insensitivity. The probiotic bacteria is at least one of Lactobacillus casei F19 (LMG P-17806), Lactobacillus acidophilus NCFB 1748 or Bifidobacterium lactis Bb12.

Claims

1. A method for the manufacture of a product, comprising:

a) providing a probiotic bacteria; and

b) adding the probiotic bacteria to at least one of milk, a cereal, a fruit, or compositions derived from milk, a cereal, or a fruit, thereby obtaining the product,

wherein the probiotic bacteria is selected from the group consisting of Lactobacillus casei, Lactobacillus acidophilus and Bifidobacterium lactis and combinations thereof.

4. A method of claim 1, wherein the probiotic bacteria is selected from the group consisting of Lactobacillus casei F19 (LMG P-17806), Lactobacillus acidophilus NCFB1748 and Bifidobacterium lactis Bb12.

5. A method of claim 1, wherein the product is a food or feed product.

6. A method of claim 1, wherein the product is a dietary supplement.

7. A method of claim 1, wherein the product is a nutritional product, a feed product, a natural remedy, a pharmaceutical active formulation, or a medicinal product.

8. A product manufactured by the method according to claim 1 which is a food product.

9. A product manufactured by the method according to claim 1 which is a feed product.

10. A product manufactured by the method according to claim 1 which is a dietary supplement, a nutritional product, a natural remedy, a pharmaceutical active formulation or a medicinal product.

12. A method according to claim 1, wherein a lactic acid bacteria different from the probiotic bacteria is added with the probiotic bacteria in b).

13. A method for controlling weight gain, comprising administering to a subject in need thereof a product manufactured by the method of claim 1.

14. A method for preventing obesity, comprising administering to a subject in need thereof a product manufactured by the method of claim 1.

15. A method for increasing satiety, prolonging satiation, reducing food intake, reducing fat deposition, enhancing insulin sensitivity, treating insulin insensitivity, treating obesity, lowering total energy intake or reducing energy intake, comprising administering to a subject in need thereof a product manufacture by the method of claim 1.

2-3. -3. (canceled)

11. A product comprising at least one of milk, a cereal, a fruit, or compositions derived from milk, a cereal, or a fruit further comprising a probiotic bacteria selected from the group consisting of Lactobacillus casei F19 (LMG P-17806), Lactobacillus acidophilus NCFB 1748 and Bifidobacterium lactis Bb12 and combinations thereof.

16. A method for decreasing the risk of developing a metabolic syndrome, the method comprising:

a) identifying a human in need of decreased risk of developing a metabolic syndrome; and

b) providing to said human a product comprising a probiotic bacteria.

17. A method according to claim 16, wherein the metabolic syndrome includes obesity, abdominal fat deposition or type II diabetes.

24. A method according to any one of claims 16-23, wherein the product further comprises at least one of milk, a cereal, a fruit, compositions derived from milk, a cereal, or a fruit.

25. A method according to any one of claims 16-23, wherein the probiotic bacteria is selected from the group consisting of Lactobacillus casei F19 (LMG P-17806), Lactobacillus acidophilus NCFB 1748, Bifidobacterium lactis Bb12 and combinations thereof.

26. A method according to any one of claims 16-23, wherein the product is administered in a portion or a daily dose which is between 1×

10⁸ CFU to 2.5×

10¹⁰ CFU.

27. A method according to any one of claims 16-23, wherein the probiotic bacteria is in the form of a concentrate.

28. A method according to any one of claims 16-23, wherein the probiotic bacteria is lyophilized.

29. The method according to any of claims 16-23, wherein the probiotic bacteria are administered as a capsule containing a dosage between 1×

10⁸ CPU to 2.5×

10¹⁰ CFU.

30. A method according to any one of claims 16-23, wherein the product her comprises a lactic acid bacteria different from the probiotic bacteria.

18. A method for lowering storage of abdominal fat, the method comprising:

a) identifying a human in need of lowering storage of abdominal fat; and

b) providing to said human a product comprising a probiotic bacteria.

19. A method for increasing satiety or prolonging satiation, the method comprising:

a) identifying a human in need of an increase in satiety or for a prolongation of satiation; and

b) providing to said human a product comprising a probiotic bacteria.

20. A method for reducing food intake or reducing energy intake, the method comprising:

a) identifying a human in need of reduction of food intake or of a reduction of energy intake; and

b) providing to said human a product comprising a probiotic bacteria.

21. A method for enhancing insulin sensitivity or treating insulin insensitivity, the method comprising:

a) identifying a human in need for an enhancement in insulin sensitivity or treatment of insulin insensitivity; and

b) providing to said human a product comprising a probiotic bacteria.

22. A method for lowering weight gain, the method comprising:

a) identifying a human in need of lowering weight gain; and

b) providing to said human a product comprising a probiotic bacteria.

33. A method according to claim 22, wherein the probiotic bacteria is selected from the group consisting of Lactobacillus casei F19 (LMG P-17806), Lactobacillus acidophilus NCFB 1748, Bifidobacterium lactis Bb12 and a combination of Lactobacillus casei F19 (LMG P-17806), and Lactobacillus acidophilus NCFB 1748.

23. A method for the up-regulation of the expression of a gene selected from the group consisting of Scd1, adiponectin (Acrp 30), adipsin (Adn), Thrsp, carbonic anhydrase 3 (Car3) and apolipoprotein A-IV (Apoa4) comprising:

a) identifying a human in need of a regulation of the expression of a gene selected from the group consisting of Scd1, adiponectin (Acrp

     30), adipsin (Adn), Thrsp, carbonic anhydrase 3 (Car3) and apolipoprotein A-IV (Apoa4); and

b) providing to said human a product comprising a probiotic bacteria.

31. A capsule comprising a probiotic bacteria selected from the group consisting of Lactobacillus casei F19 (LMG P-17806), Lactobacillus acidophilus NCFB 1748 and Bifidobacterium lactis Bb12 and combinations thereof.

32. A composition comprising a probiotic bacteria selected from the group consisting of Lactobacillus casei F19 (LMG P-17806), Lactobacillus acidophilus NCFB 1748 and Bifidobacterium lactis Bb12 and combinations thereof.